News & Views
Telix Pharmaceuticals Japan K.K. is pleased to announce the completion of Phase I enrolment of the Company’s Phase I/II ZIRDAC-JP study of Telix’s renal cancer diagnostic imaging product TLX250-CDx (89Zr-girentuximab)…
Read more
Telix and Eczacıbaşı-Monrol Nuclear Products Co. are pleased to announce that the first patients have been dosed in Telix’s Phase III ZIRCON clinical…
Read more
Telix sponsored a session at the recent EANM20 Satellite Symposium, entitled “Next Generation Imaging with PSMA-PET & More”. For those unable to attend, we are pleased to provide recordings of…
Read more
Telix Pharmaceuticals is pleased to announce we are participating at AusBiotech + Invest 2020 online conference to be held live 28th – 30th October 2020 and on-demand. Telix is pleased…
Read more
Telix Pannounces FDA has granted Orphan Drug Designation (ODD) for O-(2-[18F]fluoroethyl)-L-tyrosine for PET imaging of…
Read more
Telix Pharmaceuticals submits NDA to US FDA for TLX591-CDx (Kit for the preparation of…
Read more
Telix announces first two patients dosed in phase I trial of lung & ovarian cancer…
Read more
Telix announces it has entered into a strategic collaboration agreement with Varian Medical…
Read more
Telix announces distribution agreement with Fleurus-based IRE Elit S.A. to distribute Telix’s prostate cancer imaging…
Read more
Telix announces the FDA has granted ODD for 4-[211At] astato-l-phenylalanine for the treatment of multiple…
Read more